CD274 and neoplasm: The latest study conducted by Li W et al. showed that in patients with PD-L1 positive (tumor area positivity score≥ 5%), the combination of tislelizumab and chemotherapy was cost-effective in China at a WTP threshold of 3 times GDP per capita, but there was a lack of research on PD-L1 negative patients (Li W et al., 2024).